Format

Send to

Choose Destination
Trends Pharmacol Sci. 2012 Apr;33(4):207-14. doi: 10.1016/j.tips.2012.01.005. Epub 2012 Mar 6.

Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.

Author information

1
Vascular Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. gsemenza@jhmi.edu

Abstract

Hypoxia-inducible factors (HIFs) mediate adaptive physiological responses to hypoxia. In human cancers that are accessible for O(2) electrode measurements, intratumoral hypoxia is common and severe hypoxia is associated with increased risk of mortality. HIF activity in regions of intratumoral hypoxia mediates angiogenesis, epithelial-mesenchymal transition, stem-cell maintenance, invasion, metastasis, and resistance to radiation therapy and chemotherapy. A growing number of drugs have been identified that inhibit HIF activity by a variety of molecular mechanisms. Because many of these drugs are already FDA-approved for other indications, clinical trials can (and should) be initiated to test the hypothesis that incorporation of HIF inhibitors into current standard-of-care therapy will increase the survival of cancer patients.

PMID:
22398146
PMCID:
PMC3437546
DOI:
10.1016/j.tips.2012.01.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center